Wednesday
07.24.2019
1:22 AM
Login form
Search
Calendar
«  May 2013  »
SuMoTuWeThFrSa
   1234
567891011
12131415161718
19202122232425
262728293031
Entries archive

My site

Main » 2013 » May » 21
Revolutionary multimode M2M technology enables industries to upgrade from legacy copper line systems to secure wireless connectivity

LAS VEGAS - Tuesday, May 21st 2013 [ME NewsWire]

(BUSINESS WIRE)-- Regulatory News:

CTIA Wireless - Gemalto (Euronext NL0000400653 GTO), the world leader in digital security, announces its Cinterion® M2M technology will provide wireless connectivity for Encore Networks’ routers deployed in mission critical applications for diverse market segments from Government, Electrical, Oil & Gas, Waste & Water, Transportation and Enterprise. Developed by Encore Networks, an industrial M2M solutions leader, its routers use Gemalto’s award-winning Cinterion® multimode M2M solution that enables industries to wirelessly gather mission critical data from legacy customer premise equipment and rapidly transmit it to centers around the country.

The Encore Networks ruggedized routers provides cellular IP connectivity using Gemalto ... Read more »
Views: 74 | Added by: africa-live | Date: 05.21.2013

Launch excellence can shorten time-to-market and deliver additional sales

LONDON - Tuesday, May 21st 2013 [ME NewsWire]

(BUSINESS WIRE)-- After years of low productivity, R&D in leading pharmaceutical and biotech companies is starting to deliver on its promises; the number of New Molecular Entities (NMEs) approved by the US FDA has leveled out and biotech companies’ share prices are rising, indicating profitable business models. Now is the time for launch. Arthur D. Little’s (ADL) latest viewpoint, ‘Launch excellence for new medicines,’ assesses the key success factors for the successful launch of new medicines.

According to ADL’s most recent project experience, launch excellence has the power to shorten time-to-market by four to six months and it can deliver additional incremental annual sales of up to €50m. In the past, it seemed natural for big pharma companies to launch NMEs in known business areas and territories. However, due to global market access ... Read more »
Views: 77 | Added by: uaeonlinenews | Date: 05.21.2013 | Comments (0)

FARMINGTON HILLS, Mich. - Tuesday, May 21st 2013 [ME NewsWire]

(BUSINESS WIRE)-- Hilco Industrial, a world leader in industrial machinery and equipment auctions, will conduct the sale of over 500 lots of seafood processing equipment formerly owned by a very large seafood company. The equipment is located in a recently updated 250,000 sq. ft. state-of-the-art processing facility in Adak, Alaska.

The equipment offered features nine fish sorting lines with conveyors, sorters and 35,000-gallon holding tanks. Nineteen pollock lines also include several heading machines. Multiple crab lines are also available, which include giller stations, cookers, coolers, dip glaze tanks, chillers and an ice flake machine. A cod liver oil processing line, other heading machines, freezers, mixers and generators will also be available.

The auction will take place at the Hilton Garden Inn in Anchorage, Alaska on Tuesday, June 18, 2013, beginning at 10:00 AM HADT. Interested parties can b ... Read more »
Views: 73 | Added by: uaeonlinenews | Date: 05.21.2013

COPENHAGEN, Denmark - Tuesday, May 21st 2013 [ME NewsWire]

(BUSINESS WIRE)-- For media outside China, Japan, UK, USA only.

Lundbeck today presented results at the American Psychiatric Association (APA) Congress from post hoc analyses in bipolar I disorder patients, which confirm that depressive symptoms are frequent during manic episodes.1

The post-hoc analyses also evaluated the efficacy of asenapine or placebo treatment (olanzapine active control) on manic and depressive symptoms in bipolar I disorder patients suffering manic episodes with mixed features as defined in DSM-5 (Diagnostic and Statistical Manual of Mental Disorders).

The analyses show that the more severe depressive symptoms are at baseline, the less likely patients will achieve remission (MADRS<=12).1 With increasing baseline severity of depressive symptoms, the post hoc analysis showed that treatment effect remained stable with asenapine but decreased with placebo.1

"We know from t ... Read more »
Views: 76 | Added by: uaeonlinenews | Date: 05.21.2013

COPENHAGEN, Denmark - Tuesday, May 21st 2013 [ME NewsWire]

(BUSINESS WIRE)-- For media outside China, Japan, UK, USA only.

Lundbeck today presented results at the American Psychiatric Association (APA) Congress from post hoc analyses in bipolar I disorder patients, which confirm that depressive symptoms are frequent during manic episodes.1

The post-hoc analyses also evaluated the efficacy of asenapine or placebo treatment (olanzapine active control) on manic and depressive symptoms in bipolar I disorder patients suffering manic episodes with mixed features as defined in DSM-5 (Diagnostic and Statistical Manual of Mental Disorders).

The analyses show that the more severe depressive symptoms are at baseline, the less likely patients will achieve remission (MADRS<=12).1 With increasing baseline severity of depressive symptoms, the post hoc analysis showed that treatment effect remained stable with asenapine but decreased with placebo.1

"We know from t ... Read more »
Views: 67 | Added by: uaeonlinenews | Date: 05.21.2013

SUNNYVALE, Calif. - Monday, May 20th 2013 [ME NewsWire]

(BUSINESS WIRE)-- DVS Sciences, Inc., a privately held innovator of novel multi-parameter single-cell analyzers and reagents for biological research technology, today announced that its CyTOF® Mass Cytometer was used in an award winning paper.

The paper, Single-Cell Mass Cytometry Adapted to Measurements of the Cell Cycle, published in Cytometry Part A (81A:552-566,2012) and authored by G.K. Behbehani, S.C. Bendall, M.R. Clutter, W.J. Fanti, G.P. Nolan, describes a pioneering method using Mass Cytometry to delineate cell cycle distributions of both normal and cancer cell populations while simultaneously immunophenotyping each cell population with 25 surface markers. The paper also describes how the technology was able to study the cell cycle phases of cells spanning the hematopoietic hierarchy in healthy human bone marrow as a prelude to later studies with cancers and other disorders of this lineage.

The C ... Read more »
Views: 72 | Added by: uaeonlinenews | Date: 05.21.2013